Benjamin G Neel Selected Research

tyrosine receptor (receptor, tyrosine)

1/2020	The Protein Tyrosine Phosphatase Receptor Delta Regulates Developmental Neurogenesis.
10/2018	SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Benjamin G Neel Research Topics

Disease

55	Neoplasms (Cancer) 09/2023 - 09/2002
15	Obesity 11/2022 - 04/2002
15	Noonan Syndrome (Female Pseudo-Turner Syndrome) 01/2021 - 08/2004
12	Insulin Resistance 01/2021 - 01/2004
10	Breast Neoplasms (Breast Cancer) 09/2023 - 08/2002
9	Leukemia 01/2023 - 03/2004
8	Ovarian Neoplasms (Ovarian Cancer) 01/2021 - 02/2012
5	Inflammation (Inflammations) 01/2021 - 01/2007
5	Hypersensitivity (Allergy) 09/2014 - 04/2002
4	Lung Neoplasms (Lung Cancer) 02/2024 - 05/2010
4	Inborn Genetic Diseases (Disease, Hereditary) 01/2020 - 09/2005
4	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2018 - 03/2008
4	LEOPARD Syndrome (Syndrome, LEOPARD) 01/2018 - 05/2010
4	Carcinogenesis 01/2016 - 09/2002
3	Moyamoya Disease (Moya-Moya Disease) 09/2023 - 01/2016
3	Hypoxia (Hypoxemia) 09/2023 - 01/2012
3	Type 2 Diabetes Mellitus (MODY) 01/2022 - 01/2005
3	Neuroblastoma 01/2017 - 12/2004
2	Adenocarcinoma 02/2024 - 08/2015
2	Carcinoma (Carcinomatosis) 01/2021 - 03/2008
2	Thrombosis (Thrombus) 12/2019 - 08/2005
2	Hematologic Neoplasms (Hematological Malignancy) 01/2017 - 04/2016
2	Hypertrophy 01/2017 - 07/2005
2	Weight Loss (Weight Reduction) 01/2015 - 09/2014
2	Weight Gain 09/2014 - 11/2011
2	Neurofibromatosis 1 (Neurofibromatosis Type I) 08/2014 - 03/2013
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 07/2013 - 03/2009
2	Body Weight (Weight, Body) 01/2012 - 08/2006
2	Juvenile Myelomonocytic Leukemia 11/2010 - 04/2009
2	Melanoma (Melanoma, Malignant) 09/2010 - 09/2002
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 02/2024
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2022
1	Splenomegaly 10/2021
1	Polycythemia (Erythrocytosis) 10/2021
1	Genomic Instability 11/2020
1	Neurodevelopmental Disorders 01/2020

Drug/Important Bio-Agent (IBA)

18	Proteins (Proteins, Gene)FDA Link 09/2023 - 08/2002
17	Protein Tyrosine PhosphatasesIBA 01/2020 - 04/2002
16	Tyrosine (L-Tyrosine)FDA Link 01/2021 - 08/2002
13	Insulin (Novolin)FDA Link 01/2022 - 04/2002
10	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2020 - 06/2004
9	LeptinIBA 11/2022 - 04/2002
9	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 01/2004
9	Non-Receptor Type 1 Protein Tyrosine PhosphataseIBA 07/2013 - 06/2004
8	Non-Receptor Type 11 Protein Tyrosine PhosphataseIBA 01/2021 - 01/2007
7	Phosphotransferases (Kinase)IBA 01/2020 - 09/2002
6	6-pyruvoyltetrahydropterin synthase (PTPS)IBA 01/2017 - 06/2004
5	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 11/2015 - 01/2007
4	Biomarkers (Surrogate Marker)IBA 02/2024 - 04/2013
4	DNA (Deoxyribonucleic Acid)IBA 09/2017 - 07/2007
4	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 05/2015 - 08/2002
3	AntibodiesIBA 01/2023 - 07/2007
3	Ascorbic Acid (Vitamin C)FDA LinkGeneric 01/2023 - 09/2017
3	LigandsIBA 01/2022 - 10/2018
3	Tyrosine Kinase InhibitorsIBA 01/2022 - 08/2015
3	Antineoplastic Agents (Antineoplastics)IBA 01/2018 - 12/2004
3	CytokinesIBA 01/2017 - 11/2006
3	ErbB Receptors (EGF Receptor)IBA 08/2015 - 01/2003
2	sotorasibIBA 02/2024 - 01/2023
2	ATPases Associated with Diverse Cellular ActivitiesIBA 09/2023 - 01/2022
2	RNA (Ribonucleic Acid)IBA 01/2022 - 09/2015
2	LipidsIBA 01/2021 - 05/2014
2	Phenobarbital (Luminal)FDA Link 11/2020 - 01/2016
2	Transcription Factors (Transcription Factor)IBA 01/2020 - 07/2005
2	tyrosine receptor (receptor, tyrosine)IBA 01/2020 - 10/2018
2	Mitogen-Activated Protein KinasesIBA 01/2020 - 03/2008
2	Reactive Oxygen Species (Oxygen Radicals)IBA 11/2019 - 01/2011
2	DioxygenasesIBA 09/2017 - 01/2016
2	PhosphotyrosineIBA 01/2017 - 01/2015
2	Small Interfering RNA (siRNA)IBA 01/2016 - 02/2012
2	GTP Phosphohydrolases (GTPases)IBA 05/2015 - 03/2013
2	Growth Hormone (Somatotropin)IBA 07/2014 - 03/2012
2	Parathyroid Hormone-Related ProteinIBA 07/2013 - 01/2013
2	IntegrinsIBA 03/2013 - 02/2004
2	Insulin ReceptorIBA 01/2012 - 08/2007
2	Sirolimus (Rapamycin)FDA Link 03/2011 - 03/2004
2	Messenger RNA (mRNA)IBA 05/2010 - 08/2002
2	Phosphatidylinositols (Phosphatidylinositol)IBA 07/2005 - 09/2002
1	adagrasibIBA 02/2024
1	Ligases (Synthetase)IBA 09/2023
1	UbiquitinIBA 09/2023
1	Adenosine Diphosphate Ribose (ADP-Ribose)IBA 04/2023
1	NAD (NADH)IBA 04/2023
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 04/2023
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2023
1	HaptensIBA 01/2023
1	5-Methylcytosine (5 Methylcytosine)IBA 01/2023
1	Peptides (Polypeptides)IBA 01/2023
1	Leptin ReceptorsIBA 01/2022
1	ruxolitinibIBA 10/2021
1	Hypoglycemic Agents (Hypoglycemics)IBA 01/2021
1	FollistatinIBA 01/2021
1	DNA-Directed DNA Polymerase (Polymerases, DNA)IBA 11/2020
1	DNA Repair EnzymesIBA 11/2020
1	IsoenzymesIBA 01/2020
1	phenothiazineIBA 01/2020
1	CollagenIBA 12/2019

Therapy/Procedure

19	Therapeutics 02/2024 - 12/2004
4	Immunotherapy 01/2023 - 04/2019
4	Drug Therapy (Chemotherapy) 01/2021 - 01/2011